2026/0247 - Invitation for Proposals under Framework Agreements 2023/438 - Human Plasma Derivatives, 2024/961 - Various Medicines, and 2025/1589 - Various Medicines for the Acquisition of Plasma-Derived Medicinal Products

This tender, identified as 2026/0247, is an invitation for proposals related to the acquisition of plasma-derived medicinal products. It falls under the umbrella of existing framework agreements, specifically agreement 2023/438 for human plasma derivatives, agreement 2024/961 for various medicines, and agreement 2025/1589 also for various medicines. The primary objective is to procure essential medicinal products derived from human plasma. This procurement is crucial for ensuring the availability of treatments that rely on these complex biological products. Interested parties are invited to submit proposals detailing their capabilities and offerings in supplying these specialized pharmaceuticals. The tender seeks to establish or replenish supply chains for these vital medical goods, ensuring continuity of care and treatment for patients requiring plasma-derived therapies. Further details regarding the specific types of plasma derivatives, quantities, delivery schedules, and technical specifications will be provided to potential bidders. This initiative underscores the importance of a robust and reliable supply of these critical medicines.

This is a supplies contract in the health and medical services, information and communication technology and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 220.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.